/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture)
Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture)

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture)

Research To Practice | Oncology Videos · Oct 5, 2026

CD20xCD3 bispecific antibodies offer potent, off-the-shelf efficacy in DLBCL, rapidly advancing into earlier lines and outpatient care.

CD20 Bispecific Antibodies Retain Efficacy in DLBCL Patients Who Previously Failed CAR T-Cell Therapy

Prior CAR T-cell therapy does not compromise the clinical efficacy of CD20 x CD3 bispecific antibodies in diffuse large B-cell lymphoma. In phase 2 trials, epcoritamab achieved a 36% complete remission rate in post-CAR T patients compared to 39% overall. Similarly, glofitumab demonstrated complete remission rates in patients with prior CAR T exposure comparable to those who were CAR T-naive, with durable remissions observed in both groups.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture) thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture)

Research To Practice | Oncology Videos·a month ago

Pandemic COVID-19 Mortality Confounded Overall Survival Benefits in Epcoritamab's Phase 3 DLBCL Trial

In the phase 3 EPCORE DLBCL-1 study comparing single-agent epcoritamab against chemoimmunotherapy, epcoritamab demonstrated markedly superior 36-month progression-free survival (27% versus 8%), but failed to show a statistically significant overall survival benefit for US regulatory endpoints. Dr. Elizabeth Budde noted this discrepancy was driven by trial execution during the COVID-19 pandemic, where a 37% COVID-19 infection rate and 17% mortality in the epcoritamab cohort compromised overall survival findings.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture) thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture)

Research To Practice | Oncology Videos·a month ago

Chemo-Free Bispecific Regimens Enable Effective DLBCL Frontline Treatment in Very Elderly Populations

Chemotherapy-free or chemo-light bispecific antibody strategies demonstrate substantial clinical activity in elderly and unfit frontline diffuse large B-cell lymphoma patients. In the phase 2 MorningSun trial evaluating single-agent mosunetuzumab, patients had a median age of 82.5 years—including a patient aged 101. The chemo-free monotherapy produced a 59% complete response rate and a 69% 1-year progression-free survival rate, presenting a viable non-toxic upfront alternative.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture) thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture)

Research To Practice | Oncology Videos·a month ago

Chemotherapy Debulking Prior to Bispecific Antibody Administration Lowers Cytokine Release Syndrome Rates

Administering initial chemotherapy debulking before introducing bispecific antibodies drastically reduces the incidence of cytokine release syndrome in upfront diffuse large B-cell lymphoma. In a phase 2 trial combining glofitumab with R-CHOP, delaying glofitumab initiation until cycle 3 achieved substantial tumor debulking first. Consequently, cytokine release syndrome dropped to 10% while achieving a 90% complete response rate and 95% MRD negativity at 12 months.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture) thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture)

Research To Practice | Oncology Videos·a month ago

Documenting CD20 Expression via Biopsy Is Essential Before Initiating Bispecific Retreatment in Relapsed DLBCL

Because CD20 x CD3 bispecific antibodies require CD20 target engagement, antigen downregulation or loss is a primary resistance mechanism in patients experiencing early relapse. Dr. Elizabeth Budde highlights that verifying CD20 expression via repeat biopsy is clinically mandatory prior to initiating bispecific treatment or determining post-relapse therapy, ensuring the target antigen remains present on lymphoma cells.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture) thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture)

Research To Practice | Oncology Videos·a month ago